A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
|Title||A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.|
|Publication Type||Journal Article|
|Year of Publication||2011|
|Authors||Buchanan, RW, Keefe RSE, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog FL, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball PM, McMahon RP, Kern RS, Robinson J, Marder SR|
|Date Published||2011 Mar 1|
|Keywords||Adolescent, Adult, cognition, Cognition Disorders, Diagnostic and Statistical Manual of Mental Disorders, Double-Blind Method, Female, GABA Agonists, Humans, Male, Middle Aged, Neuropsychological Tests, Psychiatric Status Rating Scales, Pyridazines, Receptors, GABA-A, Schizophrenia, Schizophrenic Psychology, Treatment Outcome, Triazoles, Young Adult|
In a previous pilot study, MK-0777--a γ-aminobutyric acid (GABA)(A) α2/α3 partial agonist--was reported to improve delayed memory and cognitive measures of prefrontal cortical function in people with schizophrenia. The current study was designed to further examine the efficacy and safety of MK-0777 for the treatment of cognitive impairments in schizophrenia.
|Alternate Journal||Biol. Psychiatry|